New mechanisms for an old drug; DHFR- and non-DHFR-mediated effects of methotrexate in cancer cells

Klinicka Onkologie

Volumn 25, Issue SUPPL.2, 2012, Pages

  Neradil, Jakub ^a,b   Pavlasova, G ^a   Veselska, R ^a,c  

^a MASARYK UNIVERSITY   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Dihydrofolate reductase; Folate metabolism; Glyoxalase system; Histone deacetylase inhibitors; Methotrexate; Methylation; Oxidative stress

Indexed keywords

ANTIOXIDANT; DIHYDROFOLATE REDUCTASE; FOLIC ACID; GLYOXALASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; METHOTREXATE;

CANCER CELL; CELL DEATH; CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; OXIDATIVE STRESS; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL DEATH; CELL DIFFERENTIATION; FOLIC ACID; FOLIC ACID ANTAGONISTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; METHOTREXATE; METHYLATION; NUCLEOTIDES; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 84872437483     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Bartyik K, Turi S, Orosz F et al. Methotrexate inhibits the glyoxalase system in vivo in children with acute lymphoid leukaemia. Eur J Cancer 2004; 40(15): 2287-2292. (Pubitemid 39348880)
2. Huang CC, Hsu PC, Hung YC et al. Ornithine decarboxylase prevents methotrexate-induced apoptosis by reducing intracellular reactive oxygen species production. Apoptosis 2005; 10(4): 895-907.
3. Lamprecht SA, Lipkin M. Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat Rev Cancer 2003; 3(8): 601-614.
4. Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev 2007; 26(1): 153-181. (Pubitemid 46452189)
5. Fotoohi AK, Albertioni F. Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk Lymphoma 2008; 49(3): 410-426. (Pubitemid 351298325)
6. Genestier L, Paillot R, Quemeneur L et al. Mechanisms of action of methotrexate. Immunopharmacology 2000; 47(2-3): 247-257. (Pubitemid 30394541)
7. Webley SD, Welsh SJ, Jackman AL et al. The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition. Br J Cancer 2001; 85(3): 446-152.
8. Muñoz-Pinedo C, Robledo G, López-Rivas A. Thymidylate synthase inhibition triggers glucose-dependent apoptosis in p53-negative leukemic cells. FEBS Lett 2004; 570(1-3): 205-210. (Pubitemid 38900982)
9. Waldman BC, Wang Y, Kilaru K et al. Induction of intrachromosomal homologous recombination in human cells by raltitrexed, an inhibitor of thymidylate synthase. DNA Repair 2008; 7(10): 1624-1635.
10. Allegra CJ, Hoang K, Yen GC et al. Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. J Biol Chem 1987; 262(28): 13520-13526. (Pubitemid 17144303)
11. Allegra CJ, Fine RL, Drake JC et al. The effect of methotrexate on intracellular folate pools in human MCF-7 breast cancer cells. Evidence for direct inhibition of purine synthesis. J Biol Chem 1986; 261(14): 6478-6485. (Pubitemid 17204161)
12. Allegra CJ, Drake JC, Jolivet J et al. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A 1985; 82(15): 4881-4885.
13. Baggott JE, Morgan SL, Vaughn WH. Differences in methotrexate and 7-hydroxymethotrexate inhibition of folate-dependent enzymes of purine nucleotide biosynthesis. Biochem J 1994; 300(3): 627-629.
14. Allegra CJ, Chabner BA, Drake JC et al. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985; 260(17): 9720-9726. (Pubitemid 15013030)
15. McGuire JJ. Anticancer antifolates: current status and future directions. Curr Pharm Des 2003; 9(31): 2593-2613. (Pubitemid 37456011)
16. Genestier L, Paillot R, Fournel S et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102(2): 322-328.
17. Merkle CJ, Moore IM, Penton BS et al. Methotrexate causes apoptosis in postmitotic endothelial cells. Biol Res Nurs 2000; 2(1): 5-14.
18. Kruman II, Wersto RP, Cardozo-Pelaez F et al. Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron 2004; 41(4): 549-561. (Pubitemid 38253067)
19. Bodner AJ, Ting RC, Gallo RC. Induction of differentiation of human promyelocytic leukemia cells (HL-60) by nucleosides and methotrexate. J Natl Cancer Inst 1981; 67(5): 1025-1030. (Pubitemid 12252089)
20. Ross SA, Jones CS, De Luca LM. Retinoic acid and methotrexate specifically increase PHA-E-lectin binding to a 67-kDa glycoprotein in LA-N-1 human neuroblastoma cells. Int J Cancer 1995; 62(3): 303-308.
21. Schwartz PM, Barnett SK, Atillasoy ES et al. Methotrexate induces differentiation of human keratinocytes. Proc Natl Acad Sci U S A 1992; 89(2): 594-598.
22. Seitz M, Zwicker M, Loetscher P. Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes. Arthritis Rheum 1998; 41(11): 2032-2038. (Pubitemid 28506694)
23. Hatse S, Naesens L, De Clercq E et al. Potent differentiation-inducing properties of the antiretroviral agent 9-(2-phosphonylmethoxyethyl) adenine (PMEA) in the rat choriocarcinoma (RCHO) tumor cell model. Biochem Pharmacol 1998; 56(7): 851-859. (Pubitemid 28458979)
24. Hohn HP, Linke M, Denker HW. Adhesion of trophoblast to uterine epithelium as related to the state of trophoblast differentiation: in vitro studies using cell lines Mol Reprod Dev 2000; 57(2): 135-145.
25. Singh R, Fouladi-Nashta AA, Li D et al. Methotrexate induced differentiation in colon cancer cells is primarily due to purine deprivation. J Cell Biochem 2006; 99(1): 146-155. (Pubitemid 44297959)
26. Serra JM, Gutiérrez A, Alemany R et al. Inhibition of c-Myc down-regulation by sustained extracellular signal-regulated kinase activation prevents the antimetabolite methotrexate- and gemcitabine-induced differentiation in non-small-cell lung cancer cells. Mol Pharmacol 2008; 73(6): 1679-1687. (Pubitemid 351724357)
27. Lin TL, Vala MS, Barber JP et al. Induction of acute lymphocytic leukemia differentiation by maintenance therapy. Leukemia 2007; 21(9): 1915-1920.
28. Hatse S, De Clercq E, Balzarini J. Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. Biochem Pharmacol 1999; 58(4): 539-555. (Pubitemid 29296875)
29. Hara A, Niwa M, Kumada M et al. Intraocular injection of folate antagonist methotrexate induces neuronal differentiation of embryonic stem cells transplanted in the adult mouse retina. Brain Res 2006; 1085(1): 33-42. (Pubitemid 43728190)
30. Hara A, Taguchi A, Aoki H et al. Folate antagonist, methotrexate induces neuronal differentiation of human embryonic stem cells transplanted into nude mouse retina. Neurosci Lett 2010; 477(3): 138-143.
31. Stover PJ. One-carbon metabolism-genome interactions in folate-associated pathologies. J Nutr 2009, 139(12): 2402-2405.
32. Vezmar S, Schüsseler P, Becker A et al. Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity. Pediatr Blood Cancer 2009; 52(1): 26-32.
33. Li M, Hu SL, Shen ZJ et al. High-performance capillary electrophoretic method for the quantification of global DNA methylation: application to methotrexate-resistant cells. Anal Biochem 2009; 387(1): 71-75.
34. Wang YC, Chiang EP. Low-dose methotrexate inhibits methionine S-adenosyltransferase in vitro and in vivo. Mol Med 2012; 18(1): 423-432.
35. Winter-Vann AM, Kamen BA, Bergo MO et al.Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc Natl Acad Sd U S A 2003; 100(11): 6529-6534.
36. Wu J, Wood GS. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol 2011; 147(4): 443-449.
37. Salbaum JM, Kappen C. Genetic and epigenomic footprints of folate. Prog Mol Biol Transl Sci 2012; 108: 129-158.
38. Mahoney SE, Yao Z, Keyes CC et al. Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas. Epigenetics 2012; 7(4): 400-408.
39. Diede SJ, Guenthoer J, Geng LN et al. DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences. Proc Natl Acad Sci U S A 2010; 107(1): 234-239.
40. Restrepo A, Smith CA, Agnihotri S et al. Epigenetic regulation of glial fibrillary acidic protein by DNA methylation in human malignant gliomas. Neuro Oncol 2011; 13(1): 42-50.
41. Hill VK, Underhill-Day N, Krex D et al. Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene 2011; 30(8): 978-989.
42. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002; 21(35): 5427-5440. (Pubitemid 34983479)
43. Yang PM, Lin JH, Huang WY et al. Inhibition of histone deacetylase activity is a novel function of the antifolate drug methotrexate. Biochem Biophys Res Commun 2010; 391(3): 1396-1399.
44. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26(37): 5541-5552. (Pubitemid 47255934)
45. Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009; 107(4): 600-608.
46. Huang WY, Yang PM, Chang YF et al. Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol 2011; 81(4): 510-517.
47. Chang CJ, Hung MC. The role of EZH2 in tumour progression. Br J Cancer 2012; 106(2): 243-247.
48. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5(9): 769-784. (Pubitemid 44348499)
49. Dell'Aversana C, Lepore I, Altucci L. HDAC modulation and cell death in the clinic. Exp Cell Res 2012; 318(11): 1229-1244.
50. Leclerc GJ, Mou C, Leclerc GM et al. Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy. Leukemia 2010; 24(3): 552-562.
51. Einsiedel HG, Kawan L, Eckert C et al. Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia. Leukemia 2006; 20(8): 1435-1436. (Pubitemid 44084058)
52. Bastian L, Einsiedel HG, Henze G et al. The sequence of application of methotrexate and histone deacetylase inhibitors determines either a synergistic or an antagonistic response in childhood acute lymphoblastic leukemia cells. Leukemia 2011; 25(2): 359-361.
53. Prasad P, Vasquez H, Das CM et al. Histone acetylation resulting in resistance to methotrexate in choroid plexus cells. J Neurooncol 2009; 91 (3): 279-286.
54. Thornalley PJ, Rabbani N Glyoxalase in tumourigenesis and multidrug resistance. Semin Cell Dev Biol 2011; 22(3): 318-325.
55. Santarius T, Bignell GR, Greenman CD et al. GLO1-A novel amplified gene in human cancer. Genes Chromosomes Cancer 2010; 49(8): 711-725.
56. Suji G, Sivakami S. DNA damage during glycation of lysine by methylglyoxal: assessment of vitamins in preventing damage. Amino Acids 2007; 33(4): 615-621. (Pubitemid 350165438)
57. Pepper ED, Farrell MJ, Nord G et al. Antiglycation effects of carnosine and other compounds on the long-term survival of Escherichia coli. Appl Environ Microbiol 2010; 76(24): 7925-7930.
58. Kalapos MP. The tandem of free radicals and methylglyoxal. Chem Biol Interact 2008; 171(3): 251-271.
59. Koizumi K, Nakayama M, Zhu WJ et al. Characteristic effects of methylglyoxal and its degraded product formate on viability of human histiocytes: a possible detoxification pathway of methylglyoxal. Biochem Biophys Res Commun 2011; 407(2): 426-431.
60. Uzar E, Koyuncuoglu HR, Uz E et al. The activities of antioxidant enzymes and the level of malondialdehyde in cerebellum of rats subjected to methotrexate: protective effect of caffeic acid phenethyl ester. Mol Cell Biochem 2006; 291(1-2): 63-68. (Pubitemid 44725303)
61. Miketova P, Kaemingk K, Hockenberry M et al. Oxidative changes in cerebral spinal fluid phosphatidylcholine during treatment for acute lymphoblastic leukemia. Biol Res Nurs 2005; 6(3): 187-195. (Pubitemid 43920964)
62. Jahovic N, Cevik H, Sehirli AO et al. Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats. J Pineal Res 2003; 34(4): 282-287. (Pubitemid 36469775)
63. Caetano NN, Campello AP, Carnieri EG et al. Effect of methotrexate (MTX) on NAD(P)+ dehydrogenases of HeLa cells: malic enzyme, 2-oxoglutarate and isocitrate dehydrogenases. Cell Biochem Funct 1997; 15(4): 259-264. (Pubitemid 27507598)
64. Babiak RM, Campello AP, Carnieri EG et al. Methotrexate: pentose cycle and oxidative stress. Cell Biochem Funct 1998; 16(4): 283-293. (Pubitemid 28523763)
65. Vardi N, Parlakpinar H, Ates B. Beneficial effects of chlorogenic acid on methotrexate-induced cerebellar Purkinje cell damage in rats. J Chem Neuroanat 2012; 43(1): 43-47.
66. Spurlock CF 3rd, Aune ZT, Tossberg JT et al. Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK. Arthritis Rheum 2011; 63(9): 2606-2616.
67. Zapletalova D, André N, Deak L et al. Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience. Oncology 2012; 82(5): 249-260.
68. Carrasco MP, Enyedy EA, Krupenko NI et al. Novel folate-hydroxamate based antimetabolites: synthesis and biological evaluation. Med Chem 2011; 7(4): 265-274.
69. Zimmermann GR, Lehár J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts Drug Discov Today 2007; 12(1 -2): 34-42.